Predicting high healthcare costs in patients with inflammatory bowel disease

The presence of psychiatric illness, use of corticosteroids, use of narcotics, low levels of hemoglobin, and high numbers of IBD-related hospitalizations predicted high-cost outcomes.
The presence of psychiatric illness, use of corticosteroids, use of narcotics, low levels of hemoglobin, and high numbers of IBD-related hospitalizations predicted high-cost outcomes.

(HealthDay News) — For patients with inflammatory bowel disease (IBD), 5 factors can predict high health care utilization and costs, according to a study published in Clinical Gastroenterology and Hepatology.

Julajak Limsrivilai, MD, from the University of Michigan in Ann Arbor, and colleagues performed a retrospective study of medical records from all patients with IBD treated from fiscal years 2013 to 2015. Clinical variables from the prior year were selected and their ability to predict IBD-related hospitalizations, emergency department visits, and treatment charges >$30,000/year in the subsequent year was examined. Correlations were examined in a multivariate model based on a 70% randomly selected cohort (1,005 patients) and validated on the other 30% (425 patients).

The researchers found that the presence of psychiatric illness, use of corticosteroids, use of narcotics, low levels of hemoglobin, and high numbers of IBD-related hospitalizations predicted high-cost outcomes. In the validation cohort, the receiver operating characteristic curve values for prediction of IBD-related hospitalizations, emergency department visits, and high charges in the following year were 0.751, 0.738, and 0.744, respectively.

"We identified 5 factors that can effectively identify patients with IBD at high risk for hospitalization, emergency department visits, and high treatment charges in the next year," the authors write. "These patients should be closely monitored and aggressively managed."

Reference

  1. Limsrivilai J, Stidham RW, Govani SM, Waljee AK, Huang W, Higgins PDR. Factors that predict high health care utilization and costs for patients with inflammatory bowel diseases. Clin Gastroenterol H. 2017. doi:10.1016/j.cgh.2016.09.012
You must be a registered member of Clinical Advisor to post a comment.

Sign Up for Free e-newsletters